Study 111-104 Recruiting
A Phase 1, Randomized, Open-Label, Sponsor-Open, Two-Sequence, Two-Period Crossover Study to Investigate the Bioequivalence of a Single Subcutaneous Dose of BMN 111 Administered Using Either a Vial and Syringe or Injector Pen in Healthy Adult Participants
Indication
Achondroplasia
Goal
Investigate the Bioequivalence of a Single Subcutaneous Dose of BMN 111 Administered Using Either a Vial and Syringe or Injector Pen in Healthy Adult Participants
Investigational therapeutic
Combination Product: BMN111 administration via Injector Pen, Drug: BMN111 administration via vial and syringe
Status
This study is currently recruiting participants
Study Type
Phase 1